The monoclonal antibody teprotumumab has been shown to be effective in chronic thyroid eye disease, reducing double vision and proptosis.
Continue reading
The latest in clinical vision science, curated by Dr. Jade Marie Lasiste
The monoclonal antibody teprotumumab has been shown to be effective in chronic thyroid eye disease, reducing double vision and proptosis.
Continue readingThis phytosterol was investigated as a possible candidate drug for Graves’ ophthalmopathy.
Continue reading